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T cells have evolved a unique system of ligand recognition
involving an antigenT cell receptor (TCR) and a coreceptor that
integrate stimuli provided by the engagement of peptide-major
histocompatibility complex (pMHC) antigens. Here, we use
altered pMHC class I (pMHCI) molecules with impaired CD8
binding (CD8-null) to quantify the contribution of coreceptor
extracellular binding to (i) the engagement of soluble tetrameric
pMHCImolecules, (ii) the kinetics of TCR/pMHCI interactions
on live cytotoxic T lymphocytes (CTLs), and (iii) the activation
of CTLs by cell-surface antigenic determinants. Our data indi-
cate that the CD8 coreceptor substantially enhances binding
efficiency at suboptimal TCR/pMHCI affinities through effects
on both association and dissociation rates. Interestingly, core-
ceptor requirements for efficient tetramer labeling of CTLs or
for CTL activation by determinants displayed on the cell surface
operated in different TCR/pMHCI affinity ranges. Wild-type
and CD8-null pMHCI tetramers required monomeric affinities
for cognate TCRs of KD<80M and35M, respectively, to
label human CTLs at 37 °C. In contrast, activation by cellular
pMHCI molecules was strictly dependent on CD8 binding only
for TCR/pMHCI interactions with KD values >200 M. Alto-
gether, our data provide information on the binding interplay
between CD8 and the TCR and support a model of CTL activa-
tion in which the extent of coreceptor dependence is inversely
correlated to TCR/pMHCI affinity. In addition, the results
reported here define the range of TCR/pMHCI affinities
required for the detection of antigen-specific CTLs by flow
cytometry.
In concert with the T cell receptor (TCR),3 the coreceptors
CD4 andCD8 participate in and enhance the process of antigen
recognition by T cells through extracellular interactions with
peptide-major histocompatibility complex (pMHC) molecules
(1–3) and amplification of ensuing signal transduction events
(4–8). CD8 molecules are predominantly expressed as  het-
erodimers on the surface of cytotoxic T lymphocytes (CTLs)
(9), but are also found in  homodimeric form on intraepithe-
lial  T lymphocytes, certain subsets of circulating activated
CTLs, and the membranes of distinct cell lineages such as  T
cells, natural killer T cells, and dendritic cells (reviewed in Ref.
10). CD8 and CD8 bind directly to invariant domains of
major histocompatibility complex class I (MHCI) molecules
(11–13). Although CD8 and CD8 bind MHCI molecules
with similar affinities (14), it is well established that CD8 is a
much poorer coreceptor for CTLs than is CD8. Indeed, an
emerging concept is that CD8 acts as an inhibitor of CTL
activation (10). More generally, recent experimental evidence
has lent credence to the hypothesis that efficient regulation of
CTL activity is mediated by modifications of CD8 coreceptor
functions in vivo. These modifications include switching to
expression of the CD8 homodimer, post-translational
changes of CD8 following activation (15, 16), and down-
regulation of CD8 expression on the cell surface (17–20). Fluc-
tuations in the partitioning and relative distribution ofTCRand
CD8 molecules on the membrane have also been proposed to
influence the interplay between the antigen receptor and core-
ceptor in the initiating steps of CTL activation. Notably, Pecht
and Gakamsky (21) proposed a model in which pre-existing
TCR-CD8 complexes constitutively formed on the surface of
non-activated CTLs are crucial for the initiation of CTL activa-
tion. This hypothesis stems from observations that blocking
CD8 engagement and disrupting T cell membrane microdo-
main organization substantially decrease the binding efficiency
and association kinetics of multimeric peptide-major histo-
compatibility complex class I (pMHCI) molecules (22). This
model, together with studies reporting that variations in the
glycosylation state and expression levels of CD8 following in
vivo antigen encounter affect the binding of pMHCImultimers
to CTLs (19, 20), suggests that inhibition of the extracellular
engagement of pMHCI by CD8 results in reduced CTL activa-
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tion and can therefore act as a mechanism to regulate the proc-
ess of antigen recognition independently from coreceptor sig-
naling properties.
The recognition efficiency of all syngeneic pMHCI epitopes
is improved byCD8 coreceptor activities.However, the absence
of the coreceptor from the cell surface or abrogation of its
engagement with MHC molecules does not inhibit T cell acti-
vation by different agonist ligands to the same extent (23–26).
Activation of a T cell by different epitope variants is thus said to
differ in its degree of coreceptor dependence. Two principal,
mutually nonexclusive explanations for this phenomenon have
been proposed in theCD8 system. First, data obtained byHoller
and Kranz (27) and others (23, 25, 28) strongly suggest that
coreceptor dependence is inversely correlated with TCR/
pMHCI affinity. In this model, CTL activation by weak agonist
ligands characterized by low affinity and short half-life interac-
tions with the TCR relies heavily on CD8 coreceptor activity.
Second, it has been proposed that positioning of the TCR vari-
able domains (V in particular) on the pMHCI platform and
the resulting overall conformation of theTCR-CD3 complex
may hamper the signaling activity of CD8 (29) and compromise
its ability to engageMHCImolecules through binding solutions
offering unfavorable positioning of the TCR/pMHCI/CD8 tri-
molecular complex (30). Therefore, in this model, coreceptor
enhancement of CTL activation depends on the geometry of
TCR engagement.
In this study, we describe a system that enabled us to examine
the effects of the pMHCI/CD8 interaction on the engagement
of antigenic ligands by CTLs as a function of TCR/pMHCI
affinity. Comparison of the influence of CD8 on the binding
efficiency of various soluble pMHCI complexes and on the cor-
responding cellular activation profiles elicited by these ligands
presented on the surface of antigen-presenting cells provides
insights into the role of the coreceptor extracellular binding
properties in CTL activation.
EXPERIMENTAL PROCEDURES
Cell Lines—The CTL clone ILA1, isolated from a healthy
donor, is specific for residues 540–548 (ILAKFLHWL) of the
catalytic subunit of the ubiquitous tumor-associated antigen
human telomerase reverse transcriptase (hTERT) presented in
associationwith human leukocyte antigen (HLA)A*0201 (HLA
A2 from hereon). Peripheral blood mononuclear cells were
stimulated by autologous antigenic presentation using the
hTERT-(540–548) peptide at 10 M in the presence of inter-
leukin-7. Three days after initial antigen exposure, interleu-
kin-2 was gradually added to the culture up to 100 units/ml.
Similar rounds of re-stimulation were repeated three times
every 12–14 days. Following successful expansion, an antigen-
specific T cell line was sorted on the basis of the expression of
the activation markers CD25 and CD69 after incubation with
the ILAKFLHWL peptide using a FACSVantage (BD Bio-
sciences). The monoclonal T cell line ILA1 was produced by
limiting dilution of this enriched line. T cells were initially
grown in RPMI 1640 medium (Sigma) supplemented with 10%
fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin, and
100g/ml streptomycin (R10) with 10%T-STIM (final volume;
BD Biosciences) and 100 units/ml interleukin-2 and containing
mixed irradiated allogeneic feeders from three unrelated
donors. The general methods employed for the generation and
maintenance of the other CTL lines used in this study were
described previously (31). Hmy2.C1R transfectant cells
expressing HLA A2 were used in all functional assays (32).
These cells were maintained in R10.
Interferon- (IFN-) ELISpot—Antigen-presenting cells
(50,000/well; Hmy2.C1R transfectants) in 100 l of R10 were
added to ELISpot plates (Millipore Corp.) coated with anti-
human IFN-monoclonal antibody (Mabtech AB). CTLs were
then added in 100l of R10. Peptides were mixed with the cells
at the indicated final concentrations. After incubation at 37 °C
for 4 h, the plates were washed six times with phosphate-buff-
ered saline, and a secondary biotinylated anti-human IFN-
monoclonal antibody (D1K, Mabtech) was added for 90 min.
The plates were then washed again, incubated with alkaline
phosphatase-conjugated streptavidin, and developed with a
colorimetric reagent according to the manufacturer’s instruc-
tions. Spots were counted using an automated ELISpot reader
(Autoimmun Diagnostika GmbH).
Degranulation Assays—These assays were carried out as
described previously (33). 10,000 CTLs weremixedwith 50,000
antigen-presenting cells in the presence of the indicated final
peptide concentrations.
Measurement of TCRDown-regulation—10,000 antigen-pre-
senting cells were prepulsed with the indicated concentrations
of peptide and washed twice with serum-free RPMI 1640
medium supplemented with penicillin, streptomycin, and
L-glutamine as above. 30,000 CTLs were added in each assay
well and incubated for 4 h at 37 °C in 96-well plates. Cells were
pelleted by centrifugation and stained with phycoerythrin-con-
jugated anti-CD3 and allophycocyanin-conjugated anti-CD8
monoclonal antibodies prior to flow cytometric analysis. Anal-
ysis was performed with a FACSCalibur flow cytometer (BD
Biosciences) using CellQuest software.
Peptides—Synthetic peptide preparations of hTERT-(865–
873), hTERT-(540–548), and monosubstituted analogs were
purchased from Pepscan Systems (Lelystad, The Netherlands).
Human immunodeficiency virus-1 (HIV-1) Gag p17-(77–85)
(SLYNTVATL) and human T cell lymphotrophic virus-1 Tax-
(11–19) (LLFGYPVYV) peptides were purchased from Invitro-
gen. The preparations used in this study were purified by mass
spectrometry by the manufacturer and showed purities95%.
Powder was initially dissolved in Me2SO and further diluted in
serum-free RPMI 1640 medium to the desired concentrations.
Protein Synthesis—Soluble biotinylated monomeric pMHCI
proteins were produced as described previously (34). Multim-
erization was performed by the addition of R-phycoerythrin-
labeled streptavidin (Molecular Probes) to aliquots to a total
pMHCI/streptavidin molar ratio of 4:1. Expression, refolding,
purification, and biotinylation of soluble TCR heterodimers
were conducted as described previously (35).
Surface Plasmon Resonance—A Biacore 3000 TM machine
(Biacore, Uppsala, Sweden) and CM-5 sensor chips were used.
Approximately 5000 response units of streptavidin were
covalently linked to the chip surface in all four flow cells using
the amino coupling kit according to themanufacturer’s instruc-
tions. Biotinylated pMHCI proteins and biotinylated control
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protein (HLA A2 PSCA1, HLA A2 MelanA, or HLA
A2(D227K/T228A)MelanA)were bound to the sensor surfaces
by flowing dilute solutions (50 g/ml) of protein over the rele-
vant streptavidin-coated flow cell. Approximately 1000
response units of protein ligandwere bound to each flow cell for
equilibrium affinity measurements. The soluble ILA1 TCR or
CD8 homodimer was then allowed to flow over the relevant
flow cells at a rate of 5l/min at the concentrations indicated in
the figures. All measurements were performed at 25 °C using
HEPES-buffered saline (0.01MHEPES, pH 7.4, 0.15 MNaCl, 3
mM EDTA, and 0.005% Surfactant P20). Responses were
recorded in real time and analyzed using BIAevaluation soft-
ware (Biacore). Equilibrium dissociation constants (KD) were
determined assuming a 1:1 interaction (A  B% AB) by plot-
ting specific equilibrium binding responses against protein
concentrations, followed by nonlinear least-squares fitting of
the Langmuir binding equation: AB  ABmax  B/(KD  B).
Conformation of the data to the Langmuir equation was con-
firmed by linear Scatchard plot analysis using Origin 6.0 soft-
ware (MicroCal, Northampton, MA). The kinetics of TCR/
pMHCI interactions were measured using sensor chips coated
with 500 response units of ligand. Analyte TCRwas flowed over
the chip at a flow rate of 50 l/min. First-order exponential
association (ka) and dissociation (kd) curves were fitted simul-
taneously by nonlinear least squares.
pMHCI Tetramer Staining and Association and Dissociation
Measurements—Staining of the various CTL lines and of the
ILA1 CTL clone with tetramers was performed at a final con-
centration of 220 nM (with respect to the monomeric pMHCI
component) unless stated otherwise. Titration staining experi-
ments performed at 37 °C with cognate and non-cognate wild-
type (WT) tetramers for clones ILA1 and 003 indicated that,
with the tetramer preparations used in this study, non-cognate
background staining remained negligible for concentrations
220 nM (data not shown). This concentrationwas thus chosen
to perform standard CTL tetramer labeling. The staining con-
ditions were 37 °C for 15 min or 4 °C for 45 min. For tetramer
association, 106 ILA1 CTLs were washed and resuspended in
150 l of phosphate-buffered saline; pMHCI tetramers were
added at a final concentration of 1 g/ml (22 nM) with respect
to monomer at t0. Aliquots of 10 l of each sample were then
taken at the indicated time points and diluted to a final volume
of 500 l in phosphate-buffered saline prior to flow cytometric
analysis. Tetramer concentrations were thus diluted 50-fold so
that further staining occurring after collection did not contrib-
ute significantly to the measured mean fluorescence intensity
(MFI). Background staining obtained by labeling ILA1 CTLs
with non-cognateHLAA2 tetramers for 30minwas subtracted
from the MFI value at each time point. All stainings for the
association kinetics were performed at room temperature.
Detailed procedures for the tetramer decay assay are described
elsewhere (36). Staining of ILA1 cells was performed with tet-
ramer concentrations of 2.2 nM for 3G WT HLA A2 and HLA
A2(D227K/T228A) tetramers, 8.8 nM for 8Y and 8T WT HLA
A2 tetramers, and 220 nM for 8Y and 8T HLA A2(D227K/
T228A) tetramers. Unless otherwise stated, CTL labeling was
performed at 37 °C in azide buffer (phosphate-buffered saline,
0.1% NaN3, and 0.5% fetal calf serum). t0 of the decay assay
refers to the addition of anti-HLA A2 monoclonal antibody
(clone BB7.2, Serotec).
Tetramer Binding Kinetics and aModel for pMHCI Tetramer
Staining—Themodel is based on the following assumptions. (i)
A pMHCI tetramer approaching the cell surface from the incu-
bation solution will initially engage a single TCR molecule. (ii)
Subsequent TCR molecules are recruited to this “singlet” clus-
ter by diffusing into the interaction radius of one of the tetramer
binding sites and engaging that site, thus forming duplet and
triplet clusters. (iii) Binding and rebinding to one of the three
available tetramer binding sites occur very rapidly, so loss of
temporarily unbound TCR molecules (by diffusion away from
the tetramer domain of interaction) is negligible comparedwith
loss by tetramer becoming unbound at all of its sites. (iv) Once
a tetramer has become unbound, it will diffuse into solution,
whereupon the TCR cluster is left with sufficient time to dis-
band and diffuse into the background of free TCR molecules
before the next tetramer binds one of these singlets from solu-
tion. (v)Within a triplet cluster, the transition from univalently
bound tetramer to bivalently bound tetramer occurs at rate 6,
where  is the single-site TCR/pMHCI binding rate (three tet-
ramer sites times two TCRs); the transition from bivalently
bound tetramer to trivalently bound tetramer occurs at rate 2
(as a single tetramer site remains available); the transition back
from trivalently bound tetramer to bivalently bound tetramer
occurs at rate 3 (three bonds), where  is the single-site disso-
ciation rate; the transition from bivalently bound tetramer to
univalently bound tetramer occurs at rate 2; and the transition
from univalently bound tetramer to unbound tetramer,
which subsequently diffuses away into the solution while the
TCR triplet dissolves, occurs at rate . The fraction of TCR
triplets with n-valently bound tetramer (n  1, 2, 3) is given
by a quasi-stationary distribution that can be derived from
the consideration of detailed balance equations based on the
transition rates. For n  1, this quasi-stationary value is
approximately (/)2/2, under the assumption that   .
This means that triplet clusters disappear at a specific rate of
(/)2/2. A similar argument can be developed for duplet
clusters, giving the fraction (/)2/3 for univalently bound
tetramers, which yields the formula (/)2/3 for the corre-
sponding specific duplet destruction rate. The univalent
fraction for singlet clusters is 1, with destruction rate . Let
Rn denote the density of clusters on the T cell surface where
n denotes the status of the cluster (n  0, 1, 2, 3; 0 is a “free”
TCR molecule). Conservation of TCR molecules on the cell
surface implies the following (Equation 1),
RT  R0 	 R1 	 2R2 	 3R3 (Eq. 1)
where RT is the total density. The intensity of the stain (I) is
assumed to be proportional to the sumR1R2R3, which can
be evaluated by calculating these values for a dynamic equilib-
rium between the various types of cluster. Singlet clusters form
at rate 
R0, where 
 is the rate at which free TCR molecules
capture a tetramer from solution. (This rate is proportional to
the concentration of tetramer in the medium.) Singlet clusters
break up at rate  and recruit free TCR molecules at 1R0.
Duplet clusters break up at a rate of (/)2/3 and recruit free
Coreceptor Dependence of CTL Activation and Tetramer Binding
AUGUST 17, 2007•VOLUME 282•NUMBER 33 JOURNAL OF BIOLOGICAL CHEMISTRY 23801
 at CA
RD
IFF U
N
IV
ERSITY
 on February 20, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
TCR molecules at 2R0. Triplet clusters break up at a rate of
(/)2/2 and are incapable of recruiting additional TCR mol-
ecules. Setting creation and destruction rates equal for each of
these species and assuming (i) that rates,
, 1, and 2 are each
proportional to theTCR/pMHCI on-rate, whereas rate  is pro-
portional to the TCR/pMHCI off-rate, and (ii) that the TCR
recruitment rates are negligible in comparison with the
break-up rates, we obtain two equations. First, the TCR conser-
vation law becomes
1  r0 	 K1/KDr0 	 2K2/KD
3r0
2 	 3K3/KD
6r0
3 (Eq. 2)
where r0R0/RT;KD is theTCR/pMHCIdissociation constant;
and K1, K2, and K3 are compound parameters absorbing the
assumed proportionality relationships with the on-rates and
off-rates. Given KD, the conservation law can be solved for r0,
and the relative intensity of the tetramer stain can then be cal-
culated from Equation 3.
R1 	 R2 	 R3/RT  r0 	 K1/KDr0 	 K2/KD
3r0
2 	 K3/KD
6r0
3
(Eq. 3)
Maximum staining intensity is attained when all TCR mole-
cules are bound at a 1:1 stoichiometry to tetramers, i.e.when all
TCR molecules are bound in singlets (R1  RT). This does not
correspond to the case in which KD becomes vanishingly small;
in that case, all TCR molecules are bound in triplets (R3 RT),
and the relative staining intensity is only one-third of the max-
imum. For data fitting, a standard least-squares procedure
was employed, with minimization of the sum of squares by
means of steepest descent. Equations 2 and 3 were solved by
bisection. Data were log-transformed prior to the formation
of the sum of squares, corresponding to a log-normal
assumption on measurement noise and the standard proce-
dure for homogenizing the variance. Estimates were
expressed as the value that minimized the sum of squares 
S.D., which is the square root of the estimated parameter
variance, being the inverse second derivative of the sum of
squares relative to the parameter, evaluated at the point esti-
mate, times the error (noise variance) estimated by the sum
of squares.
According to the kinetic assumptions listed above, the estab-
lishment of pMHCI tetramer equilibrium staining is described
by a complex nonlinear six-dimensional dynamic system. The
staining intensity (I) is described by the following ordinary dif-
ferential equation (Equation 4),

I  
RT  efftI (Eq. 4)
where eff(t) is a time-varying effective rate constant, which is a
well defined function of the six-dimensional state of the system.
Empirically, it is found that the association kinetics are an
excellent fit to the biphasic exponential model
It  Imax,fast1 exp	fastt	 Imax,slow1 exp	slowt
(Eq. 5)
(see Fig. 6, A and B). The parameters of this equation were
determined by nonlinear least squares. It follows from Equa-
tion 5 that eff relaxes to steady-state value eff(∞), which can
be calculated from the parameter estimates according to the
formula (Imax,fastfast  Imax,slowslow)/(Imax,fast  Imax,slow).
RESULTS
Diverse pMHCI Binding Patterns Reflect Distinct Recogni-
tion Properties in Polyclonal and Monoclonal CTL Popula-
tions—Various CTL lines specific for HLA A2-restricted
viral (HIV-1 Gag p17-(77–85) and human T cell lymphotro-
phic virus-1 Tax-(11–19)) or tumor-derived (hTERT-(865–
873)) peptides were established from antigen-experienced or
antigen-naı¨ve individuals and stained with cognate WT or
CD8-null pMHCI tetramers (Fig. 1, A and B); the latter were
constructed from HLA A2 monomers containing a double
D227K/T228A mutation in the 3 domain, which abrogates
binding to the CD8 coreceptor (32). In CTL lines derived from
antigen-experienced individuals, both WT and CD8-null
pMHCI tetramers identified cognate T cell populations of sim-
ilar magnitude. However, the CD8-null tetramers consistently
stained with lower MFI values compared with the WT tetram-
ers at identical concentrations (Fig. 1, A and B). In contrast, a
line specific for human T cell lymphotrophic virus-1 Tax-(11–
19) derived from an antigen-naı¨ve individual (SH) stained only
with the corresponding WT pMHCI tetramer. Furthermore,
antigen-responsive CTLs expanded from a naı¨ve background
by successive autologous stimulations with the hTERT-(865–
873) peptide failed to bind either WT or CD8-null pMHCI tet-
ramers at any concentration (Fig. 1A) (data not shown), yet
produced IFN- when exposed to cognate peptide (Fig. 1C).
These data indicate that functional CTL populations can
exhibit discrete tetramer binding profiles and CD8 depen-
dences. Similar observations applied to different CTL clones
(Fig. 1D) (data not shown). These distinct patterns of pMHCI
tetramer binding correlated with the efficiency of antigen rec-
ognition in IFN- release assays (Fig. 1E). Overall, these results
indicate that CTLs with high levels of functional avidity can be
selectively identified with CD8-null pMHCI tetramers, as re-
ported previously (37–39), whereas functional CTLs with low
antigen sensitivity fail to bindWTorCD8-null pMHCI tetramers.
Functional and Biophysical Characterization of hTERT-
(540–548) Altered Peptide Ligands with Different Stimulatory
Activities—Systematic screening of a library of monosubsti-
tuted peptide variants using the ILA1 CTL clone enabled us to
identify an array of ligands that elicited distinct functional out-
comes in cellular activation assays (data not shown). Two weak
agonist, three superagonist, and an antagonist peptide were
selected for further study (Fig. 2 andTable 1). The affinity of the
ILA1 TCR for these various ligands was measured in surface
plasmon resonance (SPR) binding equilibrium experiments.
Themeasured dissociation constants spanned a wide spectrum
of values (Fig. 3 and Table 1), from KD values of 1 M (close to
the highest measured syngeneic interaction affinities) for 3G
and 3G8T variants to high KD values corresponding to very
weak interactions (242M for 5Y). ILA1 TCR binding to the 8E
weak agonist was so weak that we were unable to determine a
reliable KD from SPR binding equilibrium experiments (Fig.
3H). Interestingly, the non-stimulatory antagonist variant 7Y
showed an affinity for the TCR substantially superior to the
Coreceptor Dependence of CTL Activation and Tetramer Binding
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weak agonist peptides 5Y and 8E (Fig. 3 andTable 1). There was
an overall correlation between the potency of the various ago-
nist ligands and their affinity for the ILA1TCR,with the notable
exception of the two high affinity superagonists 3G and 3G8T.
Despite KD values almost 10-fold lower than those measured
for the two best superagonists (8Y and 8T), these two variants
were less stimulatory in all cellular activation assays (Fig. 2 and
Table 1) (data not shown). These results further serve to high-
light that TCR/pMHC affinity is not the main correlate of
ligand potency for cellular activation. Partial analysis of ILA1
agonist pMHCI kinetic parameters was carried out to deter-
mine whether these ligands complied with the kinetic proof-
reading model of T cell activation and whether the high
affinity for the ILA1 TCR of the relatively weak potency
ligands 3G and 3G8T could be explained by unusual kinetic
features such as very fast on-rates. The association rate con-
stant (kon) for the 3G antigen was indeed substantially faster
than those for the other ligands studied (Fig. 4 and Table 1).
However, for the 3G altered peptide ligand, the dissociation
rate constant (koff) for the TCR/pMHCI interaction was
twice as slow compared with the most potent agonist, 8T
(Table 1). Thus, the low potency of 3G compared with 8T
could not be explained solely by the kinetic proofreading
model. The kinetic parameters of the interaction between
the ILA1 TCR and the weakest agonists 5Y and 8E were too
fast for reliable measurement (Fig. 4). Nevertheless, it was
apparent that the ILA1 TCR exhibited specific binding to
both of these ligands. Comparison of the response unit traces
FIGURE1.HeterogeneouspMHCI tetramer stainingpatterns invariouspolyclonal andmonoclonalCTLpopulations.A andB, HLAA2-restrictedCTL lines
fromantigen-experiencedor antigen-naı¨ve donors, as indicated above eachgraph,were stainedwith cognateWT (A) or CD8-null (B) pMHCI tetramers at a final
concentration of 220 nM (10g/ml). The frequency of tetramer-positive cells as a percentage of the total CD8 population (upper right quadrant) and the FL-2
MFI of the CD8/tetramer-positive population (lower right quadrant) are indicated in each case. C, in the case of the tetramer-negative CTL line specific for
hTERT-(865–873), autologous presentation of cognate peptide resulted in antigen-specific activation in IFN- ELISpot assays; representative data are shown.
D, the HLA A2-restricted CTL clones identified on the x axis were stained with cognate WT (black bars) and CD8-null (white bars) pMHCI tetramers. Antigen
specificitieswere as follows: 003 and SLY-10, HIV-1Gagp17-(77–85); ILA1, hTERT-(540–548); and 1C2, hTERT-(865–873). The 1C2 clonewas isolatedby limiting
dilution from the hTERT-(865–873) line depicted in A and C; experiments using 1C2 and antigen-presenting cells of different HLA haplotypes confirmed that
hTERT-(865–873) presentationwasHLAA2-restricted (data not shown). Clones 003 and SLY-10were derived fromHIV-infected donors; clone ILA1was derived
from an antigen-naı¨ve individual. E, the peptide dose-response characteristics (“functional avidity”) of the clones shown in D were assessed in IFN- ELISpot
activation assays with Hmy2.C1R cells transduced with WT HLA A2 as antigen-presenting cells as described under “Experimental Procedures.” The average
number of spot-forming units and S.D. bars calculated from duplicates are shown.
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for the 5Y and 8E ligands (Fig. 4, E and F) confirmed that 8Ewas
amuchpoorer ligand than 5Y.Although it is not possible to give
an accurate affinity for binding to the 8E variant from these
experiments, it is clear that the KD was500 M.
Tetramer Staining and TCR/pMHCI Interaction Affinity—
The intensity or brightness of T cell labeling using pMHC tet-
ramers is generally thought to be an indicator of functional
avidity and efficiency of antigen recognition in both MHCI
(40, 41) and MHCII (42) systems. In the case of pMHCI
tetramers, invariant binding of the CD8 coreceptor is also
known to influence staining intensity. We used the ILA1
system to study the efficiency of pMHCI tetramer binding in
relation to the affinity of the monomeric TCR/pMHCI inter-
action. At 37 °C, ILA1 CTLs stained at similar intensities
with WT tetramers for which the monomeric pMHCI com-
plex exceeded an affinity threshold for the TCR (KD 
 25
M); progressive decreases in tetramer binding were
observed at higher KD values (Fig. 5, A and C). Similar results
were obtained with the corresponding CD8-null tetramers,
although the drop-off set in at substantially higher affinities
(KD 
 10 M) (Fig. 5, B and C). Staining was even more
stringent when performed at 4 °C (Fig. 5D). In each case, the
drop-off was sharp (occurring within about half a decade).
This can be understood on the basis of tetramer binding
kinetics. The monomeric KD contributes to both the forma-
tion and persistence of a tetrameric bond to a TCR triplet
cluster on the cell surface, yielding six multiplicative steps in
the kinetics (see “Experimental Procedures” for details). Fit-
ting a mathematical model to these kinetics indicated that
the pMHCI/CD8 interaction prolongs the average mono-
meric TCR/pMHCI dwell time by a factor 2.3, in keeping
with earlier estimates based on tetramer dissociation exper-
iments (36).
Coreceptor Engagement and Soluble pMHCI Association and
Dissociation Kinetics—A recent study documented that block-
ing the engagement between MHCI molecules and the CD8
coreceptor slows pMHCI tetramer association at the cell sur-
face (22). As anti-CD8 antibodies seem to have a range of effects
on pMHCI tetramer binding that do not reflect only disruption
of the pMHCI/CD8 interaction (43, 44), we sought to repro-
duce this observation in the ILA1 system using CD8-null
pMHCI tetramers. Three pMHCI ligands that showed signifi-
cant staining in tetrameric form in the absence of CD8 binding
(3G, 8T, and 8Y) (Fig. 5B) were selected for real-time binding
analysis (Fig. 6, A and B). Data fitting showed a marked differ-
ence in the effective association rates between WT and CD8-
FIGURE 2. Functional characterization of hTERT-(540–548) peptide ana-
logswith the ILA1CTLclone.A, thepeptidevariants 5Yand8E showedweak
agonist properties as determined in IFN- ELISpot assays compared with the
hTERT-(540–548) index peptide. B, three peptide variants (3G, 8T, and 8Y)
showed improved stimulatory activity compared with the hTERT-(540–548)
index peptide in IFN- ELISpot assays. C, immortalized B cells prepulsed with
the 8T superagonist peptide (10	9 M) and incubated with the indicated con-
centrations of the 7Y antagonist or an irrelevant control peptidewere used to
stimulate ILA1 CTLs; RANTES (regulated on activation normal T cell expressed
and secreted) release into the culture supernatantwasmeasured by enzyme-
linked immunosorbent assay (R&D Systems) according to themanufacturer’s
instructions. D, shown is the antagonism of ILA1. CTL degranulation was
measured by CD107a mobilization onto the cell surface; the assay was per-
formed as described previously (33). Antigen-presenting cells were pre-
pulsed with the 8T peptide (10	9 M) and incubated with the indicated con-
centrations of the 7Y peptide (E) for 6 h. Control experiments in which the
irrelevant human T cell lymphotrophic virus-1 Tax-(11–19) peptide (F) was
added inplace of the 7Y antagonistwere conducted in parallel. Relative activ-
ity represents the ratiobetween thepercentageofCD107a-positiveCTLs acti-
vatedby 8Tpeptide-pulsedB cells incubatedwith the indicatedpeptides and
the percentage of CD107a-positive CTLs activated by 8T peptide-pulsed B
cells only. In A, B, and D, assays were performed in duplicates; mean values
and S.D. bars are shown. In A and B, ELISpot assays were performed using 250
cells/well.
TABLE 1
Recognition efficiency, binding equilibrium, and kinetic parameters of the epitope variants recognized by ILA1
EC50 values were determined from dose-response curves obtained by fitting the data of degranulation assays (see “Experimental Procedures”) to a nonlinear sigmoidal
equation. The average EC50 value and S.D. for each ligandwere calculated from three different experiments. NR, variants not recognized onCD8-null targets; ND, could not
be reliably determined.
Parameter Ligand8E 5Y Index 3G 8T
Log EC50 (M)
WTHLA A2 (3.55 1) 10	7 (8.45 1) 10	8 (2.7 0.5) 10	8 (3.1 1.25) 10	9 (9.7 2.33) 10	10
HLA A2(D227K/T228A) NR NR (6.7 0.66) 10	8 (1.34 0.4) 10	8 (3.4 0.15) 10	9
KD (M)a 500 242 20 36.6 6.25 3.7 0.28 27.6 4.71
kon (M1 s1) —b —b 4.1 10	3 1.6 10	4 4 10	3
koff (s1) —b —b 0.13 0.047 0.095
KD (M)c ND ND 32 2.9 23.75
Interaction t1⁄2 (s)d 5.33 14.75 7.3
a Determined from binding equilibrium experiments (see Fig. 3).
b Too fast for reliable measurement.
c Calculated from the kinetic parameters (KD koff/kon).
d Calculated using the formula t1⁄2 ln 2/koff.
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FIGURE3.Affinitymeasurementsof the interactionbetween the ILA1TCRandvarious cognatepMHCI ligands.The results fromnonlinear analysis of SPR
binding equilibrium experiments using soluble TCRs at a maximum concentration of 100 or 300 M and 2-fold dilutions thereof flowed over immobilized
pMHCI complexes are shown here. KD values were determined by analyzing the data in nonlinear curve fittings to the equation AB  B  ABmax/(KD  B)
assuming 1:1 Langmuir binding. Mean KD values and the corresponding S.D. values are shown for each ligand. The integrity of pMHCI proteins was verified by
examining CD8 binding using SPR (data not shown). Binding to the 8E variant was so weak that it failed to approach equilibrium even with the highest
concentration of TCR utilized. Our estimates from both equilibrium binding and kinetic (Fig. 4) experiments with this ligand suggest a binding KD of2 mM.
However, these estimates arepotentially subject to substantial errors. Comparisonwith experimentswith the 5Y ligand (also see Fig. 4) confirmed that the ILA1
TCR interaction with the 8E variant ligand must be extremely weak (KD 500 M).
FIGURE 4. Kinetic measurements of ILA1 TCR interactions with five different agonist pMHCI ligands. Upper panels, SPR kinetic measurements were
performedwith five serial 2-fold dilutions of 50M ILA1 TCR for the index (A), 3G (B), and8T (C) variants. Theplots showdata and curve fitting from two separate
experiments. Similar results (5%) were obtained from three separate experiments with these protein preparations and from three other experiments using
separately prepared pMHCI and TCR preparations. Lower panels, 10 serial dilutions at a higher TCR concentration (300M)were used in an attempt tomeasure
the binding with weak agonists ligands. Data obtained with the index ligand (D) were comparable with those obtained with the lower concentration (A) of
separately prepared TCR and pMHCI. However, the kinetics were too fast for accurate measurement for the 8E (E) and 5Y (F) ligands. All pMHCI ligands bound
equally well to the CD8 protein (data not shown).
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null pMHCI tetramers, consistent with observations by Gaka-
msky et al. (22). Calculation of eff(∞) for tetramer staining
kinetics (see “Experimental Procedures”) revealed that abroga-
tion of the pMHCI/CD8 interaction substantially reduced the
capture rate of soluble pMHCI tetramers by ILA1 CTLs. This
reduction was estimated to be 61% for 3G, 85% for 8Y, and 90%
for 8T.4 The stabilizing effect of the coreceptor was also
assessed in the ILA1 system using pMHCI tetramer decay
assays (Fig. 6,C andD). In the case of 8T and 8Y altered peptide
ligands, increasing the concentration ofCD8-null tetramers did
not result in staining intensity values similar to those obtained
withWT tetramers used at 220 nM (data not shown); to achieve
similarMFI values for stainings with both types of tetramer, the
concentrations of theWTHLAA2 tetramers were adjusted. As
reported previously (36), abrogation of the pMHCI/CD8 inter-
action markedly enhanced the tetrameric pMHCI dissociation
rate. All three selected pMHCI complexes (3G, 8T, and 8Y)
displayed similar dissociation patterns regardless of their
respective affinities for the TCR. The interaction half-lives and
dissociation kinetics for all three ligands in WT pMHCI tet-
rameric formwere nearly identical (Fig. 6C); the same held true
for these ligands in CD8-null pMHCI tetrameric form,
although in each case, the t1⁄2 values were approximately three
times smaller. The increased avidity afforded by ligandmultim-
erization thus seemed to have similar consequences on the sta-
bility of each complex regardless of the affinity of the corre-4 H. A. van den Berg et al., manuscript in preparation.
FIGURE 5. Staining of ILA1 CTLs with tetramerized cognate pMHCI molecules. Shown is the staining of CTL clone ILA1 with seven different hTERT-
(540–548) variants, as indicated, refolded with WT HLA A2 (A) or CD8-null HLA A2(D227K/T228A) (B) at 37 °C. The MFI values observed with pMHCI
tetramer staining are plotted versus the TCR/pMHCI interaction KD values for experiments conducted at 37 °C (C) and 4 °C (D) withWTHLAA2 (circles) and
CD8-null HLA A2 (squares) molecules for each variant added at a final concentration of 220 nM (10 g/ml). Color codes correspond to those shown in A
and B. Staining with the set of altered peptide ligands refolded with each type of heavy chain was performed at least three times. Representative data
are shown. Curves are the best fit of the model described under “Experimental Procedures,” with estimates as follows: background staining, 2.32 
0.213; CD8 half-life prolongation factor (WT over CD8-null), 2.29 0.08; K2(WT), 10.4 1.06M; K3(WT), 27.7 0.86M; K1 fixed at 0M; andmaximumMFI
signal fixed at 225.
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sponding monovalent interactions. Similarly, the coreceptor
stabilizing effect monitored by the tetramer decay assays was
nearly identical for all variants tested, as predicted previously
(36).
Coreceptor Binding Is Strictly Required for the Engagement of
Low Affinity Ligands by CTLs—The functional effects of
pMHCI/CD8 binding on cellular activation mediated by the
ligands characterized in this study was assessed using
Hmy2.C1R cells stably expressing eitherWT or CD8-null HLA
A2molecules (45). IFN- release and CD107a up-regulation on
the cell surface were monitored (Fig. 7). In the context of the
high affinity agonist ligands 8T and index, activation of ILA1
with antigen-presenting cells expressing either WT or CD8-
null HLA A2 molecules showed a similar dynamic range of
peptide concentrations (Fig. 7,A,B, E, and F). In contrast, abro-
gation of coreceptor binding inhibited activation by the low
affinity peptide variants 5Y and 8E (Fig. 7, C, D, G, and H).
Productive engagement of the lower affinity pMHCI ligands by
the ILA1 TCR could be achieved
only in the presence of coreceptor
engagement even at high peptide
densities. Thus, the degree of core-
ceptor dependence for CTL activa-
tion seems to be inversely correlated
with the affinity and half-life of the
TCR/pMHCI interaction.
DISCUSSION
The experimental system de-
scribed here enabled us to quantify
the contribution made by CD8
invariant binding to cognate
ligand engagement by CTLs under
standardized conditions. Using
soluble multimerized ligands, we
have shown that CD8 substantially
improves the binding efficiency of
cognate pMHCI molecules with
intermediate to low affinities for
the TCR. The observation that
CD8 binding increases the num-
ber of stably bound pMHCI com-
plexes can be explained by
enhancement of the association
and/or reduction of the dissocia-
tion rates. The present data support
a role for the coreceptor in both
phenomena (Fig. 6). From a func-
tional point of view and in light of
the kinetic discrimination model of
T cell activation, the increase in
individual TCR/pMHCI dwell times
enabled by CD8 engagement would
be expected to make a significant
contribution to the well character-
ized enhancing effect that the core-
ceptor confers on the sensitivity of
antigen recognition (36). In addi-
tion, as proposed by Pecht andGakamsky (21), enhancement of
the pMHCI association rate by CD8may also increase the over-
all number of productively engaged TCR complexes and
thereby enhance the antigenicity of cognate ligands.
The magnitude of the coreceptor effect on the binding effi-
ciency of cognate pMHCI molecules was clearly influenced by
monomeric TCR/pMHCI affinities. At saturating concentra-
tions of ligand, abrogation of CD8 engagement substantially
reduced binding of tetrameric pMHCI molecules exhibiting
affinities for the TCR with KD values in the range of 10–30 M
(Fig. 5). For TCR/pMHCI interactions with KD 30 M, core-
ceptor engagement became obligatory for tetramer binding. In
contrast, functional assays with the same epitopes presented on
the cell surface pointed to a lesser role for pMHCI/CD8 extra-
cellular binding in the process of CTL activation. In cellular
activation experiments, dramatic inhibitory effects upon abro-
gation of pMHCI/CD8 engagement were observed only in the
case of the weakest agonists tested (5Y and 8E), even though all
FIGURE 6. Real-time measurements of pMHCI tetramer association and dissociation rates. Cell-surface
association of various hTERT-(540–548) peptide variants refolded with WT HLA A2 (A) and HLA A2(D227K/
T228A) (B) molecules was assessed by flow cytometry as described under “Experimental Procedures.” Data
were fitted according to the biphasic exponential association equation (Equation 5). A, the association rate
constants (fast) of the fast phase derived from data analysis were 3.08min
	1 for 3G, 8.1min	1 for 8T, and 3.07
min	1 for 8Y in the case ofWTHLAA2. In the slowphase, the association rate constants (slow)were 4.01min
	1
for 3G, 7.81min	1 for 8T, and 4.45min	1 for 8Y. B, in the context of HLA A2(D227K/T228A) tetramers, k1 values
were 0.18min	1 for 3G, 0.14min	1 for 8T, and 0.12min	1 for 8Y; k2 association constants were 0.07min
	1 for
3G, 0.13min	1 for 8T, and 0.13min	1 for 8Y. Estimation of time-varying effective rates (eff; see “Experimental
Procedures”), reflecting the overall staining kinetics, were as follows. ForWTHLAA2 tetramers,eff valueswere
1.53 for 3G, 3.11 for 8T, and 1.3 for 8Y; for HLAA2(D227K/T228A) tetramers, eff valueswere 0.76 for 3G, 2.34 for
8T, and 1.25 for 8Y. Consistent with the lower intensity staining observed in Fig. 5, the 8T and 8Y CD8-null
tetramers exhibited substantially lower maximum staining levels in these association experiments. For the
decay assays, azide-poisoned ILA1 CTLs were stained with pMHCI tetramers at concentrations that resulted in
equivalent fluorescence intensities (MFI100) for each ligand in both WT (C) and CD8-null (D) forms. Data
were fitted to the one-phase exponential decay equation: y(t) (ymax	 ymin) (1	 exp(	koff t)) ymin.
Interaction half-lives (t1⁄2 0.69/kD) were 5.62min for 3G, 3.37min for 8T, and 3.42min for 8Y in the context of
WTHLAA2molecules and 1.5min for 3G, 1.18min for 8T, and 1.14min for 8Y in the context of CD8-null HLAA2
molecules. Stainings were carried out under identical conditions at least three times. Representative data are
shown.
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of the different ligands tested showed a slight reduction in
potency (Fig. 7 and Table 1). The 5Y variant displayed an affin-
ity for the ILA1 TCR at the low end of previously characterized
TCR/pMHCI interactions with a KD of 242 M (Fig. 3). Both
kinetic parameters and equilibrium binding analysis demon-
strated that the ILA1 TCR bound to the 8E variant with an
extremely low binding affinity (KD  500 M). However, this
ligand still elicited substantial activation in functional assays.
Interestingly, the antigenicity of both the 5Y and 8E pMHCI
complexes was entirely dependent on intact MHCI/coreceptor
interactions. This suggests that enhancement of the TCR/
pMHCI association rate mediated by CD8 is crucial in deter-
mining the antigenicity of low affin-
ity ligands with unusual kinetic fea-
tures. Thus, although the degree of
coreceptor dependence for tet-
ramer binding andCTL activation is
similarly dependent on monomeric
TCR/pMHCI affinity, there is a
quantitative disparity between the
binding effects of the coreceptor on
soluble pMHCI engagement and on
activation by cell-surface determi-
nants. Such a differential contribu-
tion of CD8 to tetramer binding and
CTL activation had been suggested
by the observation that CD8-nega-
tive cells bearing a TCR specific for
an HLA A2-restricted hepatitis C
virus epitope cannot bind tetram-
ers, but are able to recognize this
epitope displayed on the surface of
antigen-presenting cells (46).
In apparent contradiction to
kinetic proofreading models of T
cell activation, the two ligands with
the highest affinities for the TCR
(Fig. 3) and the longest half-lives
(3G and 3G8T) were not the most
potent agonists (Figs. 2 and 4 and
Table 1) (data not shown). Such
inadequate behavior by T cell
ligands has been described previ-
ously and has prompted researchers
to develop and modify the kinetic
proofreading concept. Notably, it
lead to the integration of the notion
of TCR-binding site plasticity, rep-
resented by the thermodynamic
variable of heat change capacity, as
an essential parameter governing T
cell activation efficiency (47, 48).
Alternatively, Yachi et al. (30) have
recently proposed that exceptions
to the kinetic proofreading dogma
may result from impaired corecep-
tor recruitment to the vicinity of the
TCR-CD3 complex because of unfa-
vorable orientation of the TCR upon binding to pMHCI. The
data we report do not support this concept. First, detailed
examination of 3G and 3G8T tetramer binding clearly indi-
cated that CD8 contributes to the enhancement of both their
association kinetics and the stability of bound complexes (Fig.
6) (data not shown), indicating that coreceptor engagement is
not compromised in the case of these two ligands. Second, acti-
vation of ILA1 with antigen-presenting cells expressing HLA
A2 molecules that cannot engage CD8 does not result in an
inversion of the hierarchy of ligand potency between 3G and
8T, as would be predicted by the kinetic proofreading model
(Fig. 7 and Table 1). Thus, our results argue in favor of a model
FIGURE 7. Effect of the CD8 coreceptor on antigenic recognitionby ILA1CTLs.A–D, the response of ILA1 to
four different agonist ligands was determined in CD107a up-regulation assays. Each agonist peptide was
presented by Hmy2.C1R cells expressing either CD8-null HLA A2(D227K/T228A) (E) or WT HLA A2 (f) mole-
cules. Results are expressed as the percentage of effector cells showing significant activation. Means  S.D.
were calculated from two sample replicates and are representative of at least two independent experiments in
each case. E–H, IFN- secretion inducedbypeptide ligandspresented in the context ofWT (f) andCD8-null (E)
HLA A2 molecules is expressed as a percentage of the total resting ILA1 CTLs added per sample. Error bars
represent the S.D. of two replicate experiments.
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in which the CD8 dependence of cellular activation correlates
with the relative affinities of the TCR for pMHCI complexes, as
demonstrated by Holler and Kranz (27) in the 2C TCR system.
However, the TCR/pMHCI affinity thresholds for CD8
dependence we observed in the human ILA1 system are very
different from those proposed by these authors; their data
showed that T cell activation is highly coreceptor-dependent
for cognate TCR/pMHCI interactions with a KD exceeding 3
M. In our system, a high degree of coreceptor dependence
was obvious only for low affinity interactions exhibiting KD
values in excess of 50 M at the very least, even though abro-
gation of pMHCI/CD8 binding resulted in a marginal
decrease in sensitivity for all high affinity ligands (Fig. 7 and
Table 1). A fundamental difference in the experimental
approach used in both studies might account for this dis-
crepancy. Holler and Kranz used hybridomas transfected or
not with CD8 and CD8 chains, whereas in our system, the
pMHCI/coreceptor interaction was impaired by point muta-
tions in the MHCI molecules. Normal levels of CD8 were
expressed in the CTLs we used, and notably, there was no
disruption to coreceptor association with the CD3 complex,
the intracellular kinase Lck, or lipid rafts. Thus, our system
dissociates the signaling functions and membrane partition-
ing roles of CD8, believed to be important in CTL activation,
from its extracellular engagement of the MHCI molecules.
Therefore, a likely explanation for the observed affinity
threshold discrepancy is that increases in the association
kinetics and stabilization of the TCR/pMHCI interaction
afforded by CD8 extracellular binding are the sole phenom-
ena accounting for the results we obtained in the ILA1 sys-
tem. In contrast, disruption of the synergistic extracellular
binding effects and intracellular coreceptor functions of
CD8 in the system of Holler and Kranz probably resulted in a
higher stringency of coreceptor dependence. A recent study
suggested that the signaling properties of CD8 act in synergy
with the TCR/pMHCI stabilization effect and are likely to
have a dominant effect in the overall enhancement of the
antigen sensitivity phenomenon conferred by the coreceptor
(49). The difference of coreceptor dependence affinity
thresholds observed in our study and in that of Holler and
Kranz fits well with this concept. The fact that the murine
pMHCI/CD8 interaction can be of 4 times higher affinity
than the equivalent human interaction (32) is also likely to
contribute to differences in the role of CD8 binding in the
two species.
Overall, our data suggest that the dynamics of CD8 cell-
surface expression, membrane segregation, and post-trans-
lational regulation known to modulate the state of respon-
siveness during T cell development alter the modalities of
pMHCI binding, with important consequences for the
engagement of lower affinity ligands in particular (Figs. 5
and 7). Notably, the differential contributions of pMHCI/
CD8 interactions to the binding of soluble cognate ligands
and CTL activation suggest that the intracellular coreceptor
activities of CD8 exert their effect at least partially independ-
ently of extracellular pMHCI/CD8 engagement. Our find-
ings also imply that rare polymorphisms in MHCI molecules
that diminish CD8 binding, such as those that occur at posi-
tion 245 in HLA A68, HLA B48 and HLA B81, alter the
influence of coreceptor engagement on CTL activation.
Our demonstration that CD8 substantially improves the
binding efficiency of cognate pMHCI molecules with interme-
diate to low binding affinity for the TCR indicates that CD8
plays an important role in T cell cross-reactivity or “polyspeci-
ficity.” It is well established that T cells are able to recognize a
very large number of different peptides (reviewed in Ref. 50).
Studies with murine hybridomas have shown that CD8 can
alter the fine specificity of allogeneic (51) and syngeneic (27)
recognition. Indeed, our own ongoing studies show that the
majority of ligands recognized by CTL cannot be recognized at
any peptide concentration in the absence of pMHCI/CD8
engagement. Thus, the CD8 coreceptor may serve to optimize
T cell polyspecificity.
From a practical perspective, our data delineate the range of
TCR/pMHCI affinities that are amenable to detection with flu-
orescent avidin-tetramerized pMHCI molecules. Ligands with
KD values 
70–80 M could be detected with WT pMHCI
tetramers in our HLA A2-restricted system, whereas CD8-null
pMHCI tetramers could label only ILA1 CTLs if the monova-
lent affinity for theTCRwas higher (KD
 30M) (Fig. 5). These
results provide biophysical validation of the observations that
CD8-null pMHCI tetramers can qualitatively distinguish CTL
populations with high functional avidity (37–39) and confirm
that staining intensity with tetramers correlates with functional
avidity and TCR/pMHCI affinity (40, 41). It should be noted
that parameters other than intrinsic affinity, such as variations
of TCR density, differences in membrane lipid organization
(52), the state of T cell activation (19, 53, 54), and differentiation
status, can also influence tetramer binding avidity and are sub-
ject to substantial variation. These considerations preclude
generalization of the tetramer staining affinity thresholds
established in the system described here, in which all of these
variables were standardized. Nevertheless, our results reveal
the limitations of tetramer technology by providing direct evi-
dence that functionally competent T cells can bear TCRs with
affinities for cognate ligands below the threshold required for
pMHCI tetramer engagement. Both human and murine “tet-
ramer-negative” functional T cells have been reported previ-
ously (55–58). In one such system, Buslepp et al. (58) measured
the affinity between the TCR and pMHCI by SPR; the KD value
of 80 M they measured is consistent with our own results.
Finally, our data suggest that soluble multimeric pMHCI mol-
ecules engineered to bind the coreceptor with enhanced affin-
ities (36) might enable the detection of cognate ligands with
extremely low affinities for the TCR, such asmight characterize
clonotypes specific for tumor-related or autologous antigens.
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